An Open-label Phase 1 Trial of the Safety and Efficacy of Daily Subcutaneous SPL-108 Injections When Used In Combination With Paclitaxel In Patients With Platinum-resistant, CD44+, Advanced Ovarian Epithelial Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 04 Mar 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SPL 108 (Primary) ; Paclitaxel
Indications Carcinoma; Ovarian cancer
Focus Adverse reactions
Sponsors Splash Pharmaceuticals

Most Recent Events

31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
16 Mar 2020 Planned End Date changed from 28 Feb 2020 to 30 Jun 2020.
28 Sep 2019 Planned End Date changed from 31 Dec 2018 to 28 Feb 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight